Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated findings from its Phase II SUMMIT Trial of neratinib in cervical cancer at the ESMO Congress 2022 in Paris.

Click to view original post